Thromb Haemost 2018; 118(08): 1382-1389
DOI: 10.1055/s-0038-1661352
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Genetic Variation in the Syntaxin-Binding Protein STXBP5 in Type 1 von Willebrand Disease Patients

Christina Lind-Halldén
1   Department of Environmental Science and Bioscience, Kristianstad University, Kristianstad, Sweden
,
Eric Manderstedt
1   Department of Environmental Science and Bioscience, Kristianstad University, Kristianstad, Sweden
,
Daniel Carlberg
1   Department of Environmental Science and Bioscience, Kristianstad University, Kristianstad, Sweden
,
Stefan Lethagen
2   Department for Coagulation Disorders, Skåne University Hospital in Malmö, Malmö, Sweden
3   National Haemophilia Center, University Hospital Rigshospitalet, Copenhagen, Denmark
4   Sobi, Stockholm, Sweden
,
Christer Halldén
1   Department of Environmental Science and Bioscience, Kristianstad University, Kristianstad, Sweden
› Author Affiliations
Further Information

Publication History

01 March 2018

08 May 2018

Publication Date:
04 July 2018 (online)

Abstract

von Willebrand factor (VWF) levels in healthy individuals and in patients with type 1 von Willebrand disease (VWD) are influenced by genetic variation in several genes, for example, VWF, ABO and STXBP5. Here, we comprehensively screen for STXBP5 variants and investigate their association with type 1 VWD in Swedish patients and controls. The coding region of the STXBP5 gene was re-sequenced in 107 type 1 VWD patients and the detected variants were genotyped in the type 1 VWD population and a Swedish control population (464 individuals). The functional effects of missense alleles were predicted in silico and the pattern of genetic variation in STXBP5 was analysed. Re-sequencing of 107 type 1 VWD patients identified three missense and three synonymous variants in the coding sequence of STXBP5. The low-frequency missense variants rs144099092 (0.005) and rs148830578 (0.029) were predicted to be damaging, but were not accumulated in patients. No other rare candidate mutations were detected. STXBP5 showed a high level of linkage disequilibrium and a low overall nucleotide diversity of π = 3.2 × 10−4 indicating intolerance to variants affecting protein function. Three previously type 1 VWD-associated single nucleotide polymorphisms were located on one haplotype that showed an increased frequency in patients versus controls. No differences in messenger ribonucleic acid abundance among haplotypes could be found using Genotype-Tissue Expression project data. In conclusion, a haplotype containing the STXBP5 Asn436Ser (rs1039084) mutation is associated with type 1 VWD and no rare STXBP5 mutations contribute to type 1 VWD in the Swedish population.

Supplementary Material

 
  • References

  • 1 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24 (03) 123-134
  • 2 Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013; 122 (23) 3735-3740
  • 3 Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV. Clearance of von Willebrand factor. J Thromb Haemost 2013; 11 (Suppl. 01) 202-211
  • 4 Smith NL, Chen MH, Dehghan A. , et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121 (12) 1382-1392
  • 5 Desch KC, Ozel AB, Siemieniak D. , et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci U S A 2013; 110 (02) 588-593
  • 6 Rydz N, Swystun LL, Notley C. , et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood 2013; 121 (26) 5228-5237
  • 7 Sanders YV, van der Bom JG, Isaacs A. , et al; WiN Study Group. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. J Thromb Haemost 2015; 13 (06) 956-966
  • 8 van Loon JE, Leebeek FW, Deckers JW. , et al. Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet 2010; 3 (06) 507-512
  • 9 Smith NL, Rice KM, Bovill EG. , et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood 2011; 117 (22) 6007-6011
  • 10 van Loon J, Dehghan A, Weihong T. , et al. Genome-wide association studies identify genetic loci for low von Willebrand factor levels. Eur J Hum Genet 2016; 24 (07) 1035-1040
  • 11 van Loon JE, Sanders YV, de Wee EM, Kruip MJ, de Maat MP, Leebeek FW. Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients. PLoS One 2012; 7 (07) e40624
  • 12 Ye S, Huang Y, Joshi S. , et al. Platelet secretion and hemostasis require syntaxin-binding protein STXBP5. J Clin Invest 2014; 124 (10) 4517-4528
  • 13 Zhu Q, Yamakuchi M, Ture S. , et al. Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion. J Clin Invest 2014; 124 (10) 4503-4516
  • 14 Yu H, Rathore SS, Gulbranson DR, Shen J. The N- and C-terminal domains of tomosyn play distinct roles in soluble N-ethylmaleimide-sensitive factor attachment protein receptor binding and fusion regulation. J Biol Chem 2014; 289 (37) 25571-25580
  • 15 Lillicrap D. Syntaxin-binding protein 5 exocytosis regulation: differential role in endothelial cells and platelets. J Clin Invest 2014; 124 (10) 4231-4233
  • 16 Lanke E, Johansson AM, Halldén C, Lethagen S. Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotype. J Thromb Haemost 2005; 3 (12) 2656-2663
  • 17 Manderstedt E, Lind-Halldén C, Lethagen S, Halldén C. Genetic variation in the von Willebrand factor gene in Swedish von Willebrand disease patients. TH Open 2018; 02: e39-e48
  • 18 Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 2011; 27 (21) 2987-2993
  • 19 Li H, Handsaker B, Wysoker A. , et al; 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. Bioinformatics 2009; 25 (16) 2078-2079
  • 20 Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 (02) 263-265
  • 21 R Development Core Team R. A language and environment for statistical computing. Vienna, Austria: the R Foundation for Statistical Computing; 2011. ISBN: 3–900051–07–0. Available at: http://www.R-project.org/ . Accessed June 1, 2018
  • 22 Shin J-H, Blay S, McNeney B, Graham J. LDheatmap: an R function for graphical display of pairwise linkage disequilibria between single nucleotide polymorphisms. J Stat Softw; 2006;16: Code Snippet 3. Available at: http://www.jstatsoft.org/ . Accessed June 1, 2018
  • 23 Nei M, Li WH. Mathematical model for studying genetic variation in terms of restriction endonucleases. Proc Natl Acad Sci U S A 1979; 76 (10) 5269-5273
  • 24 Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4 (07) 1073-1081
  • 25 Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013; ;Chapter 7: 20
  • 26 Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7 (08) 575-576
  • 27 Flood VH, Christopherson PA, Gill JC. , et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood 2016; 127 (20) 2481-2488
  • 28 Manderstedt E, Lind-Halldén C, Lethagen S, Halldén C. Genetic variation in the C-type lectin receptor CLEC4M in type 1 von Willebrand Disease patients. PLoS One 2018; 13 (02) e0192024